Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic HemodialysisClapton Dias, Kenneth Todd Moore, Joe Murphy et al.|American Journal of Nephrology|2016Cited by 132
Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic ImpairmentJohn P. Gibbs, Maurice G. Emery, J. Greg Slatter et al.|The Journal of Clinical Pharmacology|2016Cited by 25
Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial ErrorClapton Dias, Jay Ariyawansa, William Smith et al.|American Journal of Nephrology|2016Cited by 0
ErratumCraig B. Langman, Jonathan A. Fridell, Danica Grujić et al.|American Journal of Nephrology|2016Cited by 0
Erratum: Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic HemodialysisClapton Dias, Kenneth Todd Moore, Judy Murphy et al.|Figshare|2017Cited by 0